Beliefs about medicines among type 2 diabetes mellitus patients in Quetta city, Pakistan: a cross-sectional assessment

Understanding Medication-Related Belief in Patients with Type 2 Diabetes: a Meta-Analytic Review

“…In the present review, the weakest dimension was General harm (2.31). In this regard, a study conducted in Europe has reported a moderate level for this dimension, this may be due to the lack of social support and appropriate awareness-raising interventions [28].…”

“…So, the patient's beliefs about medication were negative and less than desirable. In order to strengthen this dimension and form positive beliefs about medication, it is necessary to increase patients' knowledge about diabetes, education, and have meetings with a health care provider [28]. A study in Singapore reported a 3.43 score for specific necessity.…”

“…The general overuse dimension has a score of 2.60 in the present study. In this regard, a study in Europe, the United States, and Australia showed that this dimension is at a moderate level, which is probably due to the lack of appropriate training programs, and the right and timely guidance [28]. A study conducted in Germany also reported a moderate value for this dimension because of the lack of knowledge about the existence of addictive drugs in the country [31] .…”

Influence of Jamaican Cultural and Religious Beliefs on Adherence to Pharmacotherapy for Non-Communicable Diseases: A Pharmacovigilance Perspective

“…Recent systematic reviews and observational studies highlight the relevance of socio-cultural determinants on adherence to pharmacotherapy among patients living with NCDs ( Dhar et al, 2017 ; Niriayo et al, 2018 ; Swihart et al, 2018 ; Shahin et al, 2019 ; Al-Ganmi et al, 2020 ; Park et al, 2020 ; Raza et al, 2020 ; Świątoniowska-Lonc et al, 2021 ); however, the dearth of published literature suggests such awareness in pharmacovigilance processes is yet to be realized. Although poor adherence to pharmacotherapy is a common predictor of adverse drug reactions; the converse is also true ( Gellad et al, 2011 ; Adem et al, 2021 ; Elangwe et al, 2020 ) and therefore enriching pharmacovigilance processes with what is referred to as ‘the patient’s voice’ may facilitate causality analysis of adverse drug reactions ( Simon et al, 2020 ).…”